Sorry, you need to enable JavaScript to visit this website.

Will elizabeth holmes go to jail reddit, trail voice change morning routine

Elizabeth Holmes concludes her evidence by issuing a series of denials.

For six days during her fraud trial, Elizabeth Holmes, the founder of the failing blood-testing business Theranos, blamed others, accused a former lover of abusing and controlling her, and reframed her actions as being in the best interests of her company.

Ms. Holmes concluded her argument on Tuesday with categorical denials.

"I don't believe I did that," she responded to a query about whether she downplayed the findings of a disastrous regulatory investigation at Theranos. She then accused her company's lawyers of "doing the majority of the talking" during the discussion.

Ms. Holmes' primary evidence, which stood out as the rarest of rarities, was concluded by the comments. Rarely are technology executives prosecuted with criminal fraud, let alone a female technology executive. Even fewer take a stand in self-defense. Her time on the stand, which is expected to conclude officially on Wednesday, marked the conclusion of a trial that has gripped the business world and been held up as a fable of Silicon Valley's fake-it-til-you-make-it culture at its peak.

Will elizabeth holmes go to jail reddit, trail voice change morning routine
In September, Elizabeth Holmes was photographed with her partner, Billy Evans. Ms. Holmes' testimony is scheduled to conclude formally on Wednesday.

Ms. Holmes, 37, has pleaded not guilty to 11 counts of fraud stemming from promises she made as CEO of Theranos, the company she started in 2003. She risks up to 20 years in prison if convicted.

Her trial is nearing its conclusion. During the coming days, either side may call last witnesses, followed by closing arguments and specific instructions to jurors for their verdict deliberations.

"The jury spent six days getting to know her," Jeffrey Cohen, an associate professor of law at Boston College, said of Ms. Holmes. "If the defense is successful, that may be the deciding factor."

The jury spent the majority of the hearings hearing witnesses speak about the specifics of Ms. Holmes' alleged deception. Theranos gained notoriety after raising $945 million in investment on the promise that its breakthrough machines could perform hundreds of tests with only a little drop of blood. Ms. Holmes became a staple on magazine covers, where she was heralded as the next Steve Jobs.

However, a 2015 Wall Street Journal exposé disclosed flaws in Theranos's blood tests, precipitating a downward spiral of regulatory crackdowns and lawsuits. Ms. Holmes was indicted in 2018 after the company was dissolved.

Prosecutors have called scores of witnesses since the trial began in September, including former board members, lab directors, employees, investors, patients, and business partners. They have exposed details about Theranos's fraudulent documents, absurd financial projections, unrealistic promises, and staged demonstrations. The dull technicalities of banking, chemistry, technology, and phlebotomy frequently occupied witnesses for hours.

Ms. Holmes' prosecution relied heavily on her emails and text messages to connect her directly to the company's troubles. Prosecutors must persuade the jury that Ms. Holmes was aware of the concerns but failed to disclose them to the investors in Theranos and to the patients who rely on the company's blood tests to make medical choices.

Mr. Holmes' attorneys attempted to demonstrate in her defense that the witnesses' accounts were more nuanced than they had indicated. Investors were chastised by defense attorneys for failing to conduct adequate due diligence on Theranos before to investing. And they attempted to blame lab directors for difficulties with Theranos's test accuracy.

Ms. Holmes sat up straight in her chair and stared straight ahead throughout, her face concealed by a mask.

After prosecutors rested their case last month, and prior to summoning Ms. Holmes to the witness, her attorneys included brief evidence from a biotechnology executive who joined Theranos' board of directors following media and regulatory scrutiny.

Ms. Holmes then gave a range of justifications for Theranos's failures. She claimed that others misread her claims about the capabilities of Theranos' technology. She stated that she felt Theranos' testing functioned until a 2015 regulatory examination uncovered a slew of issues and prompted the company to nullify its tests. She claimed she lacked the necessary qualifications to run a laboratory and relied on the statements of others.

Additionally, she acknowledged to including pharmaceutical company logos in a series of studies, implying that the drugmakers had backed Theranos's technology when they had not. She expressed regret for this.

Her direct testimony concluded with the shocking admission that Ramesh Balwani, her former boyfriend, business partner, and alleged co-conspirator, had tortured her emotionally and physically. She testified through tears that Mr. Balwani had complete control over every aspect of her life — including her schedule, nutrition, and presentation — and had even coerced her into having sex with him.

She cried up again during cross-examination when prosecutors asked her to read text conversations between her and Mr. Balwani that revealed a more affectionate side to their relationship. Prosecutors got many further admissions of guilt from Ms. Holmes, including sorrow for her handling of the Journal exposé and a favorable Fortune cover story about the corporation that was later extensively amended.

Prosecutors focused their attention this week on the gaps between Ms. Holmes' testimony and what investors claimed she told them. Numerous Theranos associates and investors testified that they believed the firm had military contracts and that its technology was used in medevacs and on battlefields.

One of the prosecutors, Robert Leach, an assistant United States attorney, repeatedly asked Ms. Holmes the same question in different variations to emphasize the lack of military contracts. She verified that the contracts did not belong to Theranos.

Mr. Leach also frequently questioned Ms. Holmes about the lack of revenue from 2007 to 2014, raising the issue for each year from 2007 to 2014. Each time, Ms. Holmes said no.

Ms. Holmes fought numerous lines of questioning from Mr. Leach by saying that she did not recall or was unaware. She also attempted to cast doubt on key details in some inquiries.

Elizabeth Holmes
Elizabeth Holmes

Ms. Holmes' attorneys questioned her for a second time Tuesday afternoon, this time with a rapid-fire string of assertions intended to refute Mr. Leach's points and rebut her original testimony. Ms. Holmes reiterated that Mr. Balwani created Theranos's inflated financial estimates and that Theranos's scientists generated reports on the company's technology.

She testified that she thought Theranos's lab was "great" until a regulatory investigation discovered deeper flaws. Ms. Holmes also regularly expressed her concern about disclosing Theranos's trade secrets as a reason for withholding information from investors and partners, stating again that she feared the company's ability to compete would be jeopardized. Discussing Theranos's usage of third-party machines, she explained, would have violated Theranos's own trade-secret policy.

Mr. Leach attempted to undermine that claim by pointing out that the majority of Theranos' investors and partners had signed nondisclosure agreements, which Ms. Holmes expected to be followed.

He added that, despite the fact that Ms. Holmes possessed a patent for some technology, a patent did not "necessarily mean the innovation detailed in the patent works." Mr. Leach inquired as to whether she had developed a tablet that analyzes blood lipids, as specified in a Theranos patent.

"Not yet," Ms. Holmes stated with a smile as she leaned into the microphone.


Shariff share buttons